Mineralys Therapeutics . Quarterly Balance Sheets Chart
Quarterly
|
Annual
Mineralys Therapeutics . Quarterly Balance Sheets Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| assets | |||||||||||
| current assets: | |||||||||||
| cash and cash equivalents | 101,788,000 | 165,007,000 | 114,091,000 | 97,274,000 | 67,856,000 | 90,418,000 | 49,304,000 | 86,300,000 | 101,140,000 | 138,246,000 | 87,701,000 |
| investments | 223,128,000 | 178,019,000 | 84,096,000 | 166,329,000 | 243,259,000 | 248,147,000 | 187,263,000 | 167,461,000 | 159,957,000 | 132,393,000 | |
| prepaid and other current assets | 10,353,000 | 11,480,000 | 7,164,000 | 4,129,000 | 6,886,000 | 8,254,000 | 12,536,000 | 11,614,000 | 8,391,000 | 4,635,000 | 2,701,000 |
| total current assets | 335,269,000 | 354,506,000 | 205,351,000 | 267,732,000 | 318,001,000 | 346,819,000 | 249,103,000 | 265,375,000 | 269,488,000 | 275,274,000 | 112,811,000 |
| property and equipment | 22,000 | 38,000 | 53,000 | 69,000 | 42,000 | 51,000 | |||||
| other assets | 433,000 | 397,000 | 499,000 | 452,000 | 449,000 | 379,000 | 51,000 | 51,000 | 51,000 | 39,000 | 1,631,000 |
| total assets | 335,724,000 | 354,941,000 | 205,903,000 | 268,253,000 | 318,492,000 | 347,249,000 | 251,636,000 | 277,555,000 | 291,217,000 | 306,435,000 | 114,442,000 |
| liabilities and stockholders’ equity | |||||||||||
| current liabilities: | |||||||||||
| accounts payable | 3,164,000 | 373,000 | 479,000 | 3,106,000 | 1,707,000 | 4,261,000 | 601,000 | 5,573,000 | 2,196,000 | 2,387,000 | 1,907,000 |
| accrued liabilities | 19,009,000 | 13,013,000 | 14,167,000 | 28,215,000 | 26,690,000 | 14,943,000 | 9,881,000 | 7,970,000 | 4,011,000 | 8,173,000 | 6,160,000 |
| total current liabilities | 22,173,000 | 13,386,000 | 14,646,000 | 31,321,000 | 28,397,000 | 19,204,000 | 10,482,000 | 13,543,000 | 6,207,000 | 10,560,000 | 8,067,000 |
| commitments and contingencies | |||||||||||
| stockholders’ equity: | |||||||||||
| common stock | 6,000 | 6,000 | 5,000 | 5,000 | 5,000 | 5,000 | 4,000 | 4,000 | 4,000 | 4,000 | 1,000 |
| additional paid-in capital | 701,548,000 | 686,278,000 | 493,770,000 | 490,499,000 | 487,320,000 | 484,256,000 | 365,858,000 | 364,327,000 | 362,565,000 | 361,289,000 | 540,000 |
| accumulated deficit | -388,003,000 | -344,729,000 | -302,518,000 | -253,572,000 | -197,230,000 | -156,216,000 | -124,708,000 | -100,319,000 | -77,559,000 | -65,418,000 | -52,810,000 |
| total stockholders’ equity | 313,551,000 | 341,555,000 | 191,257,000 | 236,932,000 | 290,095,000 | 328,045,000 | 241,154,000 | 264,012,000 | 285,010,000 | 295,875,000 | |
| total liabilities and stockholders’ equity | 335,724,000 | 354,941,000 | 205,903,000 | 268,253,000 | 318,492,000 | 347,249,000 | |||||
| investments, noncurrent | 2,482,000 | 12,129,000 | 21,678,000 | 31,122,000 | |||||||
| liabilities, convertible preferred stock, and stockholders’ equity | |||||||||||
| series a convertible preferred stock, 0.0001 par value, 0 and 86,332,216 shares authorized and 0 and 86,332,216 shares issued and outstanding as of december 31, 2023 and 2022, respectively, 0 and 41,180 aggregate liquidation preference as of december 31, 2023 and 2022, respectively | |||||||||||
| series b convertible preferred stock, 0.0001 par value, 0 and 136,510,868 shares authorized and 0 and 136,510,868 shares issued and outstanding as of december 31, 2023 and 2022, respectively, 0 and 118,000 aggregate liquidation preference as of december 31, 2023 and 2022, respectively | |||||||||||
| stockholders’ equity | |||||||||||
| total liabilities, convertible preferred stock, and stockholders’ equity | 251,636,000 | 277,555,000 | 291,217,000 | 306,435,000 | |||||||
| series a convertible preferred stock, 0.0001 par value, 0 and 86,332,216 shares authorized and 0 and 86,332,216 shares issued and outstanding as of september 30, 2023 and december 31, 2022, respectively, 0 and 41,180 aggregate liquidation preference as of september 30, 2023 and december 31, 2022, respectively | |||||||||||
| series b convertible preferred stock, 0.0001 par value, 0 and 136,510,868 shares authorized and 0 and 136,510,868 shares issued and outstanding as of september 30, 2023 and december 31, 2022, respectively, 0 and 118,000 aggregate liquidation preference as of september 30, 2023 and december 31, 2022, respectively | |||||||||||
| series a convertible preferred stock, 0.0001 par value, 0 and 86,332,216 shares authorized and 0 and 86,332,216 shares issued and outstanding as of june 30, 2023 and december 31, 2022, respectively, 0 and 41,180 aggregate liquidation preference as of june 30, 2023 and december 31, 2022, respectively | |||||||||||
| series b convertible preferred stock, 0.0001 par value, 0 and 136,510,868 shares authorized and 0 and 136,510,868 shares issued and outstanding as of june 30, 2023 and december 31, 2022, respectively, 0 and 118,000 aggregate liquidation preference as of june 30, 2023 and december 31, 2022, respectively | |||||||||||
| series a convertible preferred stock, 0.0001 par value, 0 and 86,332,216 shares authorized and 0 and 86,332,216 shares issued and outstanding as of march 31, 2023 and december 31, 2022, respectively, 0 and 41,180 aggregate liquidation preference as of march 31, 2023 and december 31, 2022, respectively | |||||||||||
| series b convertible preferred stock, 0.0001 par value, 0 and 136,510,868 shares authorized and 0 and 136,510,868 shares issued and outstanding as of march 31, 2023 and december 31, 2022, respectively, 0 and 118,000 aggregate liquidation preference as of march 31, 2023 and december 31, 2022, respectively | |||||||||||
| marketable securities | 22,409,000 | ||||||||||
| liabilities, convertible preferred stock, and stockholders’ deficit | |||||||||||
| series a convertible preferred stock, 0.0001 par value, 86,332,216 and 86,340,911 shares authorized and 86,332,216 and 61,180,259 shares issued and outstanding as of december 31, 2022 and 2021, respectively, 41,180 and 29,184 aggregate liquidation preference as of december 31, 2022 and 2021, respectively | 40,987,000 | ||||||||||
| series b convertible preferred stock, 0.0001 par value, 136,510,868 and 0 shares authorized and 136,510,868 and 0 shares issued and outstanding as of december 31, 2022 and 2021, respectively, 118,000 and 0 aggregate liquidation preference as of december 31, 2022 and 2021, respectively | 117,657,000 | ||||||||||
| stockholders’ deficit: | |||||||||||
| total stockholders’ deficit | -52,269,000 | ||||||||||
| total liabilities, convertible preferred stock, and stockholders’ deficit | 114,442,000 | ||||||||||
| operating expenses: | |||||||||||
| research and development | 26,250,000 | ||||||||||
| general and administrative | 5,229,000 | ||||||||||
| total operating expenses | 31,479,000 | ||||||||||
| income from operations | -31,479,000 | ||||||||||
| other income: | |||||||||||
| interest income | 1,676,000 | ||||||||||
| change in fair value of convertible notes | |||||||||||
| other income | 4,000 | ||||||||||
| total other income | 1,680,000 | ||||||||||
| net income | -29,799,000 | ||||||||||
| net income per share | -5,770 | ||||||||||
| weighted-average shares used for eps calculation | 5,167,296,000 |
We provide you with 20 years of balance sheets for Mineralys Therapeutics . stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Mineralys Therapeutics .. Explore the full financial landscape of Mineralys Therapeutics . stock with our expertly curated balance sheets.
The information provided in this report about Mineralys Therapeutics . stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.